Free tool
FAERS Monitor: Sunlenca
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215973 or its brand name (Sunlenca, Lenacapavir Sodium). Reports on generic versions are filed under their own applications.
Reports
2
Serious
1
50% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dizziness1
- human immunodeficiency virus transmission1
- hyperhidrosis1
- maternal exposure during pregnancy1
- nausea1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 1 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,157 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| human immunodeficiency virus transmission | 1 | 38003.9 | 9457.1 | 9,466 |
| maternal exposure during pregnancy | 1 | 118.0 | 29.5 | 29 |
| hyperhidrosis | 1 | 81.6 | 20.4 | 20 |
| dizziness | 1 | 21.1 | 5.3 | 4 |
| nausea | 1 | 13.3 | 3.3 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.